Amplia Therapeutics (ATX) AI Stock Analysis

• Market Cap: AU$25.60M
• Dividend Yield: N/A
• Average Volume (3M): 3.20M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.85
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: AU
• Employees: 1
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 387,952,670
• 10 Day Avg. Volume: 1,746,884
• 30 Day Avg. Volume: 3,196,432
• PEG Ratio: 0.09
• Price to Book (P/B): 1.07
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.59
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: ―

Amplia Therapeutics Ltd. faces significant challenges with profitability and cash flow, despite strong revenue growth. The technical analysis indicates a bearish market sentiment, and valuation metrics reflect the high risk associated with early-stage biotech firms. Investors should be cautious and consider these factors before investing.

Amplia Therapeutics Business Overview & Revenue Model

Company Description

Amplia Therapeutics Ltd. (ATX) is a biotechnology company specializing in the development of targeted therapies for cancer and fibrotic diseases. The company focuses on advancing its proprietary drug candidates through clinical trials, aiming to address unmet medical needs in oncology and fibrosis treatment. With a commitment to innovative research, Amplia Therapeutics leverages its expertise in small molecule drugs to create effective therapeutic solutions.

How the Company Makes Money

Amplia Therapeutics Ltd. generates revenue primarily through the development and commercialization of its drug candidates. The company aims to advance its proprietary compounds through clinical trials and regulatory approvals, ultimately leading to successful commercialization and sales. Revenue streams may include licensing agreements with larger pharmaceutical companies, milestone payments, and royalties from sales of approved drugs. Amplia Therapeutics may also engage in strategic partnerships or collaborations to enhance its research capabilities and expand its market reach, contributing to its earnings.

Amplia Therapeutics Financial Statement Overview

Summary

Amplia Therapeutics Ltd. shows robust revenue growth but struggles with profitability, as reflected by negative EBIT and net profit margins. The balance sheet is stable with low leverage, but challenges persist in cash flow management, typical for early-stage biotech firms.

Income Statement

Amplia Therapeutics Ltd. has demonstrated strong revenue growth, with a substantial increase from last year. However, profitability remains a challenge, as evidenced by negative EBIT and net profit margins. The company continues to operate at a loss, which is typical in the biotechnology sector but requires attention for future sustainability.

Balance Sheet

The company's balance sheet shows a reasonable equity position with an equity ratio of 77%. However, the debt-to-equity ratio of 0.14 indicates some level of financial leverage. The balance sheet suggests stability, but the decrease in total assets and stockholders' equity over the past year may warrant careful monitoring.

Cash Flow

Cash flow analysis shows negative operating and free cash flow, which is concerning and typical for early-stage biotech firms. The operating cash flow to net income ratio suggests difficulty in generating positive cash flow relative to net losses. However, the company's ability to manage financing activities provides some level of mitigation.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement		Total Revenue
3.41M	4.45M	1.19M	1.98M	1.53M	34.23K
	Gross Profit
3.01M	4.01M	1.12M	1.98M	1.53M	33.42K
	EBIT
-6.10M	-4.42M	-7.48M	-5.63M	-3.88M	-2.26M
	EBITDA
-6.24M	-4.56M	-7.26M	-3.64M	-2.34M	-2.22M
	Net Income Common Stockholders
-6.19M	-4.50M	-6.24M	-3.64M	-2.28M	-2.22M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
3.20M	3.39M	9.26M	14.61M	1.85M	1.11M
	Total Assets
5.03M	14.85M	18.68M	24.48M	10.88M	9.12M
	Total Debt
0.00	1.59M	2.27M	2.10M	0.00	0.00
	Net Debt
-3.20M	-1.80M	-6.99M	-12.51M	-1.85M	-1.11M
	Total Liabilities
1.03M	3.43M	2.85M	2.64M	539.13K	510.62K
	Stockholders Equity
4.00M	11.42M	15.84M	21.85M	10.34M	8.61M
Cash Flow		Free Cash Flow
-2.76M	-5.13M	-5.31M	-4.42M	―	-2.09M
	Operating Cash Flow
-2.76M	-5.13M	-5.29M	-4.40M	-2.92M	-2.09M
	Investing Cash Flow
-2.62K	-2.23K	-58.42K	-26.64K	―	0.00
	Financing Cash Flow
1.68M	-772.98K	-84.22K	17.19M	3.66M	1.96M

Amplia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.07
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ATX, the sentiment is Positive. The current price of 0.07 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.06, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 65.77 is Neutral, neither overbought nor oversold. The STOCH value of 72.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ATX.

Amplia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RAC	54 Neutral	AU$205.01M	―	-37.20%	―	―	32.02%
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
PIQ	51 Neutral	AU$68.68M	―	-131.55%	―	12.53%	-11.04%
ATX	46 Neutral	AU$25.60M	―	-41.60%	―	―	―
CYP	43 Neutral	AU$38.41M	―	-75.39%	―	―	44.29%

Amplia Therapeutics Corporate Events

Amplia Therapeutics’ ACCENT Trial Shows Promising Results in Pancreatic Cancer Treatment

Amplia Therapeutics Ltd. presented interim data from its ACCENT trial at the AACR annual meeting, showcasing the promising efficacy of its FAK inhibitor, narmafotinib, in combination with chemotherapy for advanced pancreatic cancer. The data indicates that narmafotinib is well tolerated and shows better outcomes compared to chemotherapy alone, with a higher disease control rate and longer median duration on trial. This development could enhance Amplia’s positioning in the oncology market and provide new hope for stakeholders involved in pancreatic cancer treatment.

Amplia Therapeutics Launches US Trial for Innovative Pancreatic Cancer Treatment

Amplia Therapeutics Limited has initiated trial activities for a new pancreatic cancer treatment in the US, combining their FAK inhibitor narmafotinib with the chemotherapy FOLFIRINOX. The trial, managed by a multinational CRO, aims to assess the safety, tolerability, and efficacy of this combination in advanced pancreatic cancer patients, potentially enhancing treatment outcomes and strengthening Amplia’s position in the oncology field.

Amplia Therapeutics Reports Promising Data from Pancreatic Cancer Trial

Amplia Therapeutics has reported promising updated data from its ongoing ACCENT trial, which is evaluating the FAK inhibitor narmafotinib in combination with chemotherapy for advanced pancreatic cancer. The trial has shown encouraging efficacy with 13 confirmed partial responses and good tolerability, suggesting that narmafotinib may enhance the effectiveness of chemotherapy. This data will be presented at the American Association of Cancer Research Annual Meeting, highlighting the drug’s potential impact on pancreatic cancer treatment and reinforcing Amplia’s position in the oncology sector.

Amplia Therapeutics Advances US Clinical Trial Plans with FDA Approval

Amplia Therapeutics announced a positive outcome from its Type D meeting with the FDA regarding its planned clinical trial in the US for narmafotinib, a FAK inhibitor, in combination with FOLFIRINOX for advanced pancreatic cancer. The FDA’s approval of the proposed changes to the trial protocol allows Amplia to proceed with final planning stages, potentially positioning narmafotinib as a preferred drug in combination therapies for pancreatic cancer, enhancing its market position and offering promising prospects for stakeholders.

Amplia Therapeutics Adjusts Option Exercise Prices Post Capital Raising

Amplia Therapeutics Limited has announced a change in the exercise prices of its unlisted options following a successful A$13 million capital raising completed in December 2024. The adjustments, set to take effect on February 20, 2025, are in line with ASX Listing Rule 6.22.2 and will involve distributing replacement holding statements and application forms to all option holders, potentially impacting stakeholder engagement and financial strategies.